Groups | VEGF | HE4 | CA125 | ||
---|---|---|---|---|---|
(pg/ml) | (pmol/L) | (U/ml) | |||
Ovarian cancer Median Range | stage I | 1/2 | 1/2 | 1 | |
166.18 | 83.50 | 63.50 | |||
15.38 -656.56 | 28.60-1093.80 | 12.00-557.20 | |||
stage II | 1/2 | 1/2 | 1/2 | ||
170.50 | 62.60 | 61.45 | |||
8.92-2701.07 | 27.00-625.10 | 9.80-998.00 | |||
stage III | 1/2/4 | 1/2/4 | 1/2/4 | ||
345.50 | 117.90 | 766.60 | |||
10.70-1429.50 | 48.70-1500.00 | 10.10-2060.78 | |||
stage IV | 1/2/4/5 | 1/2/4 | 1/2/4 | ||
143.50 | 198.00 | 531.90 | |||
9.00-1386.00 | 37.80-1944.20 | 14.30-8602.30 | |||
Total group | 1/2 | 1/2 | 1/2 | ||
168.48 | 103.60 | 133.30 | |||
8.92-2701.07 | 27.00-1944.20 | 9.80-8602.30 | |||
Serous epithelial | 1/6 | 1/6/7/9 | 1/6/7 | ||
166.18 | 126.00 | 171.21 | |||
8.92-1429.50 | 28.60-1944.20 | 9.80-8602.30 | |||
Endometrioid epithelial | 1/6 | 1/6/7 | 1/6/7 | ||
184.24 | 68.45 | 114.00 | |||
9.00-2701.07 | 27.00-1740.00 | 11.10-1425.00 | |||
Control groups Median Range | Benign ovarian tumor (Cystis) | Endometrioides | 3/8 | ||
45.50 | 23.15 | 43.75 | |||
9.00-560.50 | 14.00-65.60 | 7.50-2748.00 | |||
Serous | 3 | 8 | 3 | ||
84.35 | 43.25 | 20.65 | |||
9.00-2100.00 | 26.80-156.40 | 5.80-451.80 | |||
Total group | 3 | ||||
68.71 | 42.50 | 27.70 | |||
9.00-2100.00 | 14.00-156.40 | 5.80-2748.00 | |||
Healthy subjects | 39.31 | 44.15 | 9.94 | ||
2.30-467.10 | 6.20-122.30 | 5.06-36.60 |